Tagraxofusp, the first CD123-targeted therapy and first targeted treatment for blastic plasmacytoid dendritic cell neoplasm

References

• Agis H, Fureder W, Bankl HC, et al. Comparative immunophenotypic analysis of human mast cells, blood basophils and monocytes. Immunology. 1996;87(4):535–543.
   PubMed Web of Science ®Google Scholar
• Jordan CT, Upchurch D, Szilvassy SJ, et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia. 2000;14(10):1777–1784.
   PubMed Web of Science ®Google Scholar
• Toba K, Koike T, Shibata A, et al. Novel technique for the direct flow cytofluorometric analysis of human basophils in unseparated blood and bone marrow, and the characterization of phenotype and peroxidase of human basophils. Cytometry. 1999;35(3):249–259.
   PubMedGoogle Scholar
• Testa U, Pelosi E, Frankel ACD. 123 is a membrane biomarker and a therapeutic target in hematologic malignancies. Biomark Res. 2014;2(1):4.
   PubMedGoogle Scholar
• Aldinucci D, Olivo K, Lorenzon D, et al. The role of interleukin-3 in classical Hodgkin’s disease. Leuk Lymphoma. 2005;46(3):303–311.
   PubMed Web of Science ®Google Scholar
• Borthakur A, Reddy R. Imaging cartilage physiology. Top Magn Reson Imaging. 2010;21(5):291–296.
   PubMedGoogle Scholar
• Djokic M, Bjorklund E, Blennow E, et al. Overexpression of CD123 correlates with the hyperdiploid genotype in acute lymphoblastic leukemia. Haematologica. 2009;94(7):1016–1019.
   PubMed Web of Science ®Google Scholar
• Florian S, Sonneck K, Hauswirth AW, et al. Detection of molecular targets on the surface of CD34+/CD38– stem cells in various myeloid malignancies. Leuk Lymphoma. 2006;47(2):207–222.
   PubMed Web of Science ®Google Scholar
• Graf M, Hecht K, Reif S, et al. Expression and prognostic value of hemopoietic cytokine receptors in acute myeloid leukemia (AML): implications for future therapeutical strategies. Eur J Haematol. 2004;72(2):89–106.
   PubMed Web of Science ®Google Scholar
• Lhermitte L, de Labarthe A, Dupret C, et al. Most immature T-ALLs express Ra-IL3 (CD123): possible target for DT-IL3 therapy. Leukemia. 2006;20(10):1908–1910.
   PubMed Web of Science ®Google Scholar
• Alayed K, Patel KP, Konoplev S, et al. TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow. Am J Hematol. 2013;88(12):1055–1061.
   PubMed Web of Science ®Google Scholar
• Angelot-Delettre F, Roggy A, Frankel AE, et al. In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent. Haematologica. 2015;100(2):223–230.
   PubMed Web of Science ®Google Scholar
• Frankel AE, Ramage J, Kiser M, et al. Characterization of diphtheria fusion proteins targeted to the human interleukin-3 receptor. Protein Eng. 2000;13(8):575–581.
   PubMedGoogle Scholar
• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405.
   PubMed Web of Science ®Google Scholar
• Feuillard J, Jacob MC, Valensi F, et al. Clinical and biologic features of CD4(+)CD56(+) malignancies. Blood. 2002;99(5):1556–1563.
   PubMed Web of Science ®Google Scholar
• Petrella T, Bagot M, Willemze R, et al. Blastic NK-cell lymphomas (agranular CD4+CD56+ hematodermic neoplasms): a review. Am J Clin Pathol. 2005;123(5):662–675.
   PubMed Web of Science ®Google Scholar
• Garnache-Ottou F, Feuillard J, Ferrand C, et al. Extended diagnostic criteria for plasmacytoid dendritic cell leukaemia. Br J Haematol. 2009;145(5):624–636.
   PubMed Web of Science ®Google Scholar
• Chaperot L, Bendriss N, Manches O, et al. Identification of a leukemic counterpart of the plasmacytoid dendritic cells. Blood. 2001;97(10):3210–3217.
   PubMed Web of Science ®Google Scholar
• Pemmaraju N, Lane AA, Sweet KL, et al. Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm. N Engl J Med. 2019;380(17):1628–1637.
   PubMed Web of Science ®Google Scholar
• Stemline Therapeutics. Lzonris (Tagraxofusp-erzs): US Prescribing Information;2018 Sep 6. [cited 2019 Aug 5]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761116s000lbl
   Google Scholar
• Suda T, Suda J, Ogawa M, et al. Permissive role of interleukin 3 (IL-3) in proliferation and differentiation of multipotential hemopoietic progenitors in culture. J Cell Physiol. 1985;124(2):182–190.
   PubMed Web of Science ®Google Scholar
• Park LS, Waldron PE, Friend D, et al. Interleukin-3, GM-CSF, and G-CSF receptor expression on cell lines and primary leukemia cells: receptor heterogeneity and relationship to growth factor responsiveness. Blood. 1989;74(1):56–65.
   PubMed Web of Science ®Google Scholar
• Ogata H, Taniguchi S, Inaba M, et al. Separation of hematopoietic stem cells into two populations and their characterization. Blood. 1992;80(1):91–95.
   PubMed Web of Science ®Google Scholar
• Ailles LE, Gerhard B, Hogge DE. Detection and characterization of primitive malignant and normal progenitors in patients with acute myelogenous leukemia using long-term coculture with supportive feeder layers and cytokines. Blood. 1997;90(7):2555–2564.
   PubMed Web of Science ®Google Scholar
• Choe S, Bennett MJ, Fujii G, et al. The crystal structure of diphtheria toxin. Nature. 1992;357(6375):216–222.
   PubMed Web of Science ®Google Scholar
• Naglich JG, Metherall JE, Russell DW, et al. Expression cloning of a diphtheria toxin receptor: identity with a heparin-binding EGF-like growth factor precursor. Cell. 1992;69(6):1051–1061.
   PubMed Web of Science ®Google Scholar
• Simpson JC, Smith DC, Roberts LM, et al. Expression of mutant dynamin protects cells against diphtheria toxin but not against ricin. Exp Cell Res. 1998;239(2):293–300.
   PubMed Web of Science ®Google Scholar
• Chiron MF, Fryling CM, FitzGerald DJ. Cleavage of pseudomonas exotoxin and diphtheria toxin by a furin-like enzyme prepared from beef liver. J Biol Chem. 1994;269(27):18167–18176.
   PubMed Web of Science ®Google Scholar
• Oh KJ, Zhan H, Cui C, et al. Organization of diphtheria toxin T domain in bilayers: a site-directed spin labeling study. Science. 1996;273(5276):810–812.
   PubMed Web of Science ®Google Scholar
• Blanke SR, Huang K, Collier RJ. Active-site mutations of diphtheria toxin: role of tyrosine-65 in NAD binding and ADP-ribosylation. Biochemistry. 1994;33(51):15494–15500.
   PubMed Web of Science ®Google Scholar
• Falnes PO, Wiedlocha A, Rapak A, et al. Farnesylation of CaaX-tagged diphtheria toxin A-fragment as a measure of transfer to the cytosol. Biochemistry. 1995;34(35):11152–11159.
   PubMed Web of Science ®Google Scholar
• Alexander RL, Kucera GL, Klein B, et al. In vitro interleukin-3 binding to leukemia cells predicts cytotoxicity of a diphtheria toxin/IL-3 fusion protein. Bioconjug Chem. 2000;11(4):564–568.
   PubMed Web of Science ®Google Scholar
• Frankel AE, Rossi P, Kuzel TM, et al. Diphtheria fusion protein therapy of chemoresistant malignancies. Curr Cancer Drug Targets. 2002;2(1):19–36.
   PubMed Web of Science ®Google Scholar
• Frankel AE, Hall PD, McLain C, et al. Cell-specific modulation of drug resistance in acute myeloid leukemic blasts by diphtheria fusion toxin, DT388-GMCSF. Bioconjug Chem. 1998;9(4):490–496.
   PubMed Web of Science ®Google Scholar
• Yalcintepe L, Frankel AE, Hogge DE. Expression of interleukin-3 receptor subunits on defined subpopulations of acute myeloid leukemia blasts predicts the cytotoxicity of diphtheria toxin interleukin-3 fusion protein against malignant progenitors that engraft in immunodeficient mice. Blood. 2006;108(10):3530–3537.
   PubMed Web of Science ®Google Scholar
• Alexander RL, Ramage J, Kucera GL, et al. High affinity interleukin-3 receptor expression on blasts from patients with acute myelogenous leukemia correlates with cytotoxicity of a diphtheria toxin/IL-3 fusion protein. Leuk Res. 2001;25(10):875–881.
   PubMed Web of Science ®Google Scholar
• Horita H, Frankel AE, Thorburn A. Acute-myeloid-leukemia-targeted toxins kill tumor cells by cell-type-specific mechanisms and synergize with TRAIL to allow manipulation of the extent and mechanism of tumor cell death. Leukemia. 2008;22(3):652–655.
   PubMed Web of Science ®Google Scholar
• Mani R, Goswami S, Gopalakrishnan B, et al. The interleukin-3 receptor CD123 targeted SL-401 mediates potent cytotoxic activity against CD34(+)CD123(+) cells from acute myeloid leukemia/myelodysplastic syndrome patients and healthy donors. Haematologica. 2018;103(8):1288–1297.
   PubMed Web of Science ®Google Scholar
• Ray A, Das DS, Song Y, et al. A novel agent SL-401 induces anti-myeloma activity by targeting plasmacytoid dendritic cells, osteoclastogenesis and cancer stem-like cells. Leukemia. 2017;31(12):2652–2660.
   PubMed Web of Science ®Google Scholar
• Hogge DE, Feuring-Buske M, Gerhard B, et al. The efficacy of diphtheria-growth factor fusion proteins is enhanced by co-administration of cytosine arabinoside in an immunodeficient mouse model of human acute myeloid leukemia. Leuk Res. 2004;28(11):1221–1226.
   PubMed Web of Science ®Google Scholar
• Kim HP, Frankel AE, Hogge DE. A diphtheria toxin interleukin-3 fusion protein synergizes with tyrosine kinase inhibitors in killing leukemic progenitors from BCR/ABL positive acute leukemia. Leuk Res. 2010;34(8):1035–1042.
   PubMed Web of Science ®Google Scholar
• Chauhan D, Singh AV, Brahmandam M, et al. Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target. Cancer Cell. 2009;16(4):309–323.
   PubMed Web of Science ®Google Scholar
• Frankel A, Liu JS, Rizzieri D, et al. Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia. Leuk Lymphoma. 2008;49(3):543–553.
   PubMed Web of Science ®Google Scholar
• Frankel AE, Woo JH, Ahn C, et al. Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood. 2014;124(3):385–392.
   PubMed Web of Science ®Google Scholar
• Feuring-Buske M, Frankel AE, Alexander RL, et al. A diphtheria toxin-interleukin 3 fusion protein is cytotoxic to primitive acute myeloid leukemia progenitors but spares normal progenitors. Cancer Res. 2002;62(6):1730–1736.
   PubMed Web of Science ®Google Scholar
• Kiser M, McCubrey JA, Steelman LS, et al. Oncogene-dependent engraftment of human myeloid leukemia cells in immunosuppressed mice. Leukemia. 2001;15(5):814–818.
   PubMed Web of Science ®Google Scholar
• Konopleva MH, Hogge D, Rizzieri DA, et al. SL-401, a targeted therapy directed to the interleukin-3 receptor present on leukemia blasts and cancer stem cells, is active as a single agent in patients with advanced AML. Blood. 2012;120:3625.
   PubMed Web of Science ®Google Scholar
• Lane ASKL, Sweet K, Wang ES, et al. Results from ongoing phase 1/2 trial of sl-401 as consolidation therapy in patients with Acute Myeloid Leukemia (AML) in remission with Minimal Residual Disease (MRD). Blood. 2017;130:2583.
   Google Scholar
• Miyauchi J, Kelleher CA, Wong GG, et al. The effects of combinations of the recombinant growth factors GM-CSF, G-CSF, IL-3, and CSF-1 on leukemic blast cells in suspension culture. Leukemia. 1988;2(6):382–387.
   PubMed Web of Science ®Google Scholar
• Frolova O, Benito J, Brooks C, et al. SL-401 and SL-501, targeted therapeutics directed at the interleukin-3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase chronic myeloid leukaemia. Br J Haematol. 2014;166(6):862–874.
   PubMed Web of Science ®Google Scholar
• Lasho T, Finke C, Kimlinger TK, et al. Expression of CD123 (IL-3R-alpha), a therapeutic target of SL-401, on myeloproliferative neoplasms. Blood. 2014;124:5577.
   Web of Science ®Google Scholar
• Pemmaraju N, Ali H, Gupta V, et al. Results from ongoing phase 1/2 clinical trial of tagraxofusp (SL-401) in patients with intermediate or high risk relapsed/refractory myelofibrosis. J Clin Oncol. 2019;37:7058.
   Web of Science ®Google Scholar
• Patnaik MM, Gupta V, Schiller GJ. Results from ongoing phase 1/2 clinical trial of tagraxofusp (SL-401) in patients with intermediate or high risk relapsed/refractory myelofibrosis. Blood. 2018;132(Suppl 1):2908.
   Google Scholar
• Pagano L, Valentini CG, Pulsoni A, et al. Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study. Haematologica. 2013;98(2):239–246.
   PubMed Web of Science ®Google Scholar
• Dalle S, Beylot-Barry M, Bagot M, et al. Blastic plasmacytoid dendritic cell neoplasm: is transplantation the treatment of choice? Br J Dermatol. 2010;162(1):74–79.
   PubMed Web of Science ®Google Scholar
• Martin-Martin L, Lopez A, Vidriales B, et al. Classification and clinical behavior of blastic plasmacytoid dendritic cell neoplasms according to their maturation-associated immunophenotypic profile. Oncotarget. 2015;6(22):19204–19216.
   PubMedGoogle Scholar
• Agha ME, Monaghan SA, Swerdlow SH. Venetoclax in a patient with a blastic plasmacytoid dendritic-cell neoplasm. N Engl J Med. 2018;379(15):1479–1481.
   PubMed Web of Science ®Google Scholar
• Montero J, Stephansky J, Cai T, et al. Blastic plasmacytoid dendritic cell neoplasm is dependent on BCL2 and sensitive to venetoclax. Cancer Discov. 2017;7(2):156–164.
   PubMed Web of Science ®Google Scholar